Brokerages Expect Cardiff Oncology, Inc. (NASDAQ:CRDF) Will Post Quarterly Sales of $80,000.00

Equities research analysts expect Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) to announce $80,000.00 in sales for the current quarter, Zacks reports. Two analysts have made estimates for Cardiff Oncology’s earnings, with estimates ranging from $50,000.00 to $100,000.00. Cardiff Oncology reported sales of $70,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 14.3%. The company is expected to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Cardiff Oncology will report full-year sales of $300,000.00 for the current financial year, with estimates ranging from $200,000.00 to $400,000.00. For the next year, analysts expect that the company will post sales of $200,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Cardiff Oncology.

Cardiff Oncology (NASDAQ:CRDF – Get Rating) last announced its quarterly earnings data on Thursday, February 24th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.06). Cardiff Oncology had a negative net margin of 7,880.50% and a negative return on equity of 21.05%. The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.07 million.

A number of equities research analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Cardiff Oncology in a research note on Tuesday, April 12th. Zacks Investment Research lowered Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, March 2nd. William Blair began coverage on Cardiff Oncology in a report on Wednesday, January 5th. They set an “outperform” rating for the company. Finally, Maxim Group reduced their target price on Cardiff Oncology from $25.00 to $14.00 in a report on Monday, January 24th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $16.25.

Shares of Cardiff Oncology stock opened at $1.53 on Tuesday. Cardiff Oncology has a 52-week low of $1.46 and a 52-week high of $10.24. The stock’s 50-day simple moving average is $2.37 and its 200 day simple moving average is $4.36. The stock has a market capitalization of $66.26 million, a P/E ratio of -2.15 and a beta of 1.84.

Hedge funds and other institutional investors have recently modified their holdings of the company. Citigroup Inc. grew its holdings in shares of Cardiff Oncology by 105.1% during the fourth quarter. Citigroup Inc. now owns 10,574 shares of the company’s stock worth $64,000 after purchasing an additional 5,419 shares in the last quarter. Metropolitan Life Insurance Co NY purchased a new stake in Cardiff Oncology in the third quarter worth approximately $74,000. Invesco Ltd. purchased a new stake in Cardiff Oncology in the second quarter worth approximately $87,000. HighVista Strategies LLC purchased a new stake in Cardiff Oncology in the third quarter worth approximately $103,000. Finally, GSA Capital Partners LLP purchased a new stake in Cardiff Oncology in the fourth quarter worth approximately $93,000. 59.52% of the stock is owned by institutional investors.

Cardiff Oncology Company Profile (Get Rating)

Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Recommended Stories